AEZS ( MC $43 M) 8 Drugs in P2 /1 Drug in P3 / 1x Awaiting FDA approval

Discussion in 'Stock picks and trading strategies' started by DollarChamp, Nov 14, 2013.

  1. DollarChamp

    DollarChamp Member

    Here is a real Big Opportunity which you can buy currently at All Time Low ,the only reason for the very low price was just a Share offering a few weeks ago .

    AEZS has already a Drug on the Market which is partnered with pharma giant Merck (MRK) , the annual revenue for the product is around $70 M thats almost two times higher than current Market Cap .

    AEZS has another Drug awaiting FDA approval and muliple Cancer Drugs in Late Stage some of them a potential Blockbusters .

    I think AEZS has the potential for runup to minimum to $4-5 before FDA decision in Mid 2014 . GL

    AEterna Zentaris (AEZS)

    Market Cap: $43 M
    Cash: $24 M
    Price: $1.35

    Shares Out: 32 M

    Annual Revenue :$ 70 M

    MEGA Pipeline

    New Presentation Public.pdf

    Fact Sheet


    Macimorelin Acetate (AEZS-130)

    Diagnostic in adult growth hormonedeficiency (endocrinology) under review by FDA

    Product ..Zoptarelin Doxorubicin (AEZS-108)

    Endometrial cancer in Phase 3

    Tripl-negative breast cancer In Phase 2

    Castration-and taxane-resistant prostate cancer in Phase 2

    Refractory bladder cancer in Phase 2

    Ovarian cancer (completed) in Phase 2

    Product ..Ozarelix :

    Prostate cancer in Phase 2

    Product ..Macimorelin Acetate (AEZS-130)

    Therapeutic in cancer cachexia in Phase 2

    Product ..Perifosine

    Multiple cancers in Phase 2

Share This Page